• 2021
• 2020
• 2019
• 2018
• 2017
• 2016
• 2015
• 2014
• 2013
• 2012
• 2011
• 2010
• 2009
• 2008
• 2007
• 2006
• 2005
• 2004
• 2003
• 2002
• 2001
• 2000
• 1999
• 1998
• 1997
• 1996
• 1995
• 1994
• 1993
• 1992
• 1980s

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

1999

1998

1997

1996

1995

1994

1993

1992

1980s

• • Ng SR, Rideout WM 3rd, Akama-Garren EH, Bhutkar A, Mercer KL, Schenkel JM, Bronson RT, Jacks T. CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer. Proc Natl Acad Sci USA. 2020. 117(1):513-521. doi: 10.1073/pnas.1821893117. Epub 2019 Dec 23. PMID: 31871154.
     
  • Chung KM, Singh J, Lawres L, Dorans KJ, Garcia C, Burkhardt DB, Robbins R, Bhutkar A, Cardone R, Zhao X, Babic A, Vayrynen SA, Dias Costa A, Nowak JA, Chang DT, Dunne RF, Hezel AF, Koong AC, Wilhelm JJ, Bellin MD, Nylander V, Gloyn AL, McCarthy MI, Kibbey RG, Krishnaswamy S, Wolpin BM, Jacks T, Fuchs CS, Muzumdar MD. Endocrine-Exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma. Cell. 2020 May 14;181(4):832-847.e18. doi: 10.1016/j.cell.2020.03.062. Epub 2020 Apr 17. PMID: 32304665.
     
  • Kirkpatrick JD, Warren AD, Soleimany AP, Westcott PMK, Voog JC, Martin-Alonso C, Fleming HE, Tammela T, Jacks T, Bhatia SN. Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. Sci Transl Med. 2020 Apr 1;12(537). pii: eaaw0262. doi: 10.1126/scitranslmed.aaw0262. PMID: 32238573.
     
  • Romero R, Sánchez-Rivera FJ, Westcott PMK, Mercer KL Bhutkar A, Muir A, González Robles TJ, Lamboy Rodríguez S, Liao LZ, Ng SR, Li L, Colón CI, Naranjo S, Beytagh MC, Lewis CA, Hsu PP, Bronson RT, Vander Heident MG, Jacks T. Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1. Nature Cancer. 2020 June 8; 1:589-602. doi: 10.1038/s43018-020-0071-1. PMID: 28967920.
     
  • Schoenfeld AJ, Bandlamudi C, Lavery JA, Montecalvo J, Namakydoust A, Rizvi H, Egger JV, Concepcion CP, Paul S, Arcila ME, Daneshbod Y, Chang JC, Sauter JL, Beras A, Ladanyi M, Jacks T, Rudin CM, Taylor BS, Donoghue MTA, Heller G, Hellmann MD, Rekhtman N, Riely GJ. The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. Clin Cancer Res. 2020 Nov 1;26(21):5701-5708. doi: 10.1158/1078-0432.CCR-20-1825. Epub 2020 Jul 24. PMID: 32709715.
     
  • Damo M, Fitzgerald B, Lu Y, Nader M, William I, Cheung JF, Connolly KA, Foster GG, Akama-Garren E, Lee DY, Chang GP, Gocheva V, Schmidt LM, Boileve A, Wilson JH, Cui C, Monroy I, Gokare P, Cabeceiras P, Jacks T, Joshi NS. Inducible de novo expression of neoantigens in tumor cells and mice. Nat Biotechnol. 2021 Jan;39(1):64-73. doi: 10.1038/s41587-020-0613-1. Epub 2020 Jul 27. PMID: 32719479.
     
  • Marjanovic ND, Hofree M, Chan JE, Canner D, Wu K, Trakala M, Hartmann GG, Smith OC, Kim JY, Evans KV, Hudson A, Ashenberg O, Porter CBM, Bejnood A, Subramanian A, Pitter K, Yan Y, Delorey T, Phillips DR, Shah N, Chaudhary O, Tsankov A, Hollmann T, Rekhtman N, Massion PP, Poirier JT, Mazutis L, Li R, Lee JH, Amon A, Rudin CM, Jacks T, Regev A, Tammela T. Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer Cell. 2020 Aug 10;38(2):229-246.e13. doi: 10.1016/j.ccell.2020.06.012. Epub 2020 Jul 23. PMID: 32707077.
     
  • LaFave LM, Kartha VK, Ma S, Meli K, Del Priore I, Lareau C, Naranjo S, Westcott PMK, Duarte FM, Sankar V, Chiang Z, Brack A, Law T, Hauck H, Okimoto A, Regev A, Buenrostro JD, Jacks T. Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma. Cancer Cell. 2020 Aug 10;38(2):212-228.e13. doi: 10.1016/j.ccell.2020.06.006. Epub 2020 Jul 23. PMID: 32707078.
     
  • Gupta M, Concepcion CP, Fahey CG, Keshishian H, Bhutkar A, Brainson CF, Sanchez-Rivera FJ, Pessina P, Kim JY, Simoneau A, Paschini M, Beytagh MC, Stanclift CR, Schenone M, Mani DR, Li C, Oh A, Li F, Hu H, Karatza A, Bronson RT, Shaw AT, Hata AN, Wong KK, Zou L, Carr SA, Jacks T, Kim CF. BRG1 loss predisposes lung cancers to replicative stress and ATR dependency. Cancer Res. 2020 Sept 15:80(18):3841-3854. doi: 10.1158/0008-5472.CAN-20-1744. Epub 2020 Jul 20. PMID: 32690724.
     
  • Lau AN, Li Z, Danai LV, Westermark AM, Darnell AM, Ferreira R, Gocheva V, Sivanand S, Lien EC, Sapp KM, Mayers JR, Biffi G, Chin CR, Davidson SM, Tuveson DA, Jacks T, Matheson NJ, Yilmaz O, Vander Heiden MG. Dissecting cell type-specific metabolism in pancreatic ductal adenocarcinoma. Elife. 2020 Jul 10;9:e56782. doi: 10.7554/eLife.56782. PMID: 32648540.
  • Li A, Herbst RH, Canner D, Schenkel JM, Smith OC, Kim JY, Hillman M, Bhutkar A, Cuoco MS, Rappazzo CG, Rogers P, Dang C, Jerby-Arnon L, Rozenblatt-Rosen O, Cong L, Birnbaum M, Regev A, Jacks T. Il-33 signaling alters regulatory T cell diversity in support of tumor development. Cell Rep. 2019. 29(10):2998-3008. e8. doi: 10.1016/j.celrep.2019.10.120.
     
  • Li L, Ng SR, Colón CI, Drapkin BJ, Hsu PP, Li Z, Nabel CS, Lewis CA, Romero R, Mercer KL, Bhutkar A, Phat S, Myers DT, Muzumdar MD, Westcott PMK, Beytagh MC, Farago AF, Vander Heiden MG, Dyson NJ, Jacks T. Identification of DHODH as a therapeutic target in small cell lung cancer. Sci Transl Med. 2019. 11(517): pii: eaaw7852. doi: 10.1126/scitranslmed.aaw7852.
     
  • Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, Meng W, Lichti CF, Esaulova E, Vomund AN, Runci D, Ward JP, Gubin MM, Medrano RFV, Arthur CD, White JM, Sheehan KCF, Chen A, Wucherpfennig KW, Jacks T, Unanue ER, Artyomov MN, Schreiber RD. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 2019. 574(7780):696-701.
     
  • Schmidt L, Eskiocak B, Kohn R, Dang C, Joshi NS, DuPage M, Lee DY, Jacks T. Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation. PNAS. 2019. 116(35): 17460-17469.
     
  • Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, Giacomelli AO, Wong W, Kim J, Chao S, Kurppa KJ, Yang X, Milenkowic K, Piccioni F, Root DE, Rücker FG, Flamand Y, Neuberg D, Lindsley RC, Jänne PA, Hahn WC, Jacks T, Döhner H, Armstrong SA, Ebert BL. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019. 365(6453):599-604.
     
  • Jaeger AM, Stopfer L, Lee S, Gaglia G, Sandel D, Santagata S, Lin NU, Trepel JB, White F, Jacks T, Lindquist S, Whitesell L. Rebalancing protein homeostasis enhances tumor antigen presentation. Clin Cancer Res. 2019. 25(21):6392-6405.
     
  • Pentinmikko N, Iqbal S, Mana M, Andersson S, Cognetta AB 3rd, Suciu RM, Roper J, Luopajärvi K, Markelin E, Gopalakrishnan S, Smolander OP, Naranjo S, Saarinen T, Juuti A, Pietiläinen K, Auvinen P, Ristimäki A, Gupta N, Tammela T, Jacks T, Sabatini DM, Cravatt BF, Yilmaz ÖH, Katajisto P. Notum produced by Paneth cells attenuates regeneration of aged intestinal epithelium. Nature. 2019. 571(7765):398-402.
     
  • Jin C, Lagoudas GK, Zhao C, Bullman S, Bhutkar A, Hu B, Ameh S, Sandel D, Liang XS, Mazzilli S, Whary MT, Meyerson M, Germain R, Blainey PC, Fox JG, Jacks T. Commensal Microbiota Promote Lung Cancer Development via gamma delta T Cells. Cell. 2019. 176(5): 998-1013.
     
  • Hamza B, Ng SR, Prakadan SM, Delgado FF, Chin CR, King EM, Yang LF, Davidson SM, DeGouveia KL, Cermak N, Navia AW, Winter PS, Drake RS, Tammel T, Li CM, Papagiannakopoulos T, Gupta AJ, Bagnall JS, Kudesen SM, Vander Heiden MG, Wasserman SC, Jacks T, Shalek AK, Manalis SR. Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer. PNAS. 2019. 116(6): 2232-2236.
  • Goggins MG, Lippman SM, Constantinou PE, Jacks T, Petersen GM, Syngal S, Maitra A. Intercepting Pancreatic Cancer: Our Dream Team's Resolve to Stop Pancreatic Cancer.Pancreas. 2018 Nov/Dec;47(10):1175-1176. doi: 10.1097/MPA.0000000000001165. No abstract available. PMID:30325853.
     
  • Guimaraes PPG, Tan M, Tammela T, Wu K, Chung A, Oberli M, Wang K, Spektor R, Riley RS, Viana CTR, Jacks T, Langer R, Mitchell MJ. Potent in vivo lung cancer Wnt signaling inhibition via cyclodextrin-LGK974 inclusion complexes. J Control Release. 2018 Oct 2;290:75-87. doi: 10.1016/j.jconrel.2018.09.025. [Epub ahead of print]. PMID:30290244.
     
  • Lo JH, Hao L, Muzumdar MD, Raghavan S, Kwon EJ, Pulver EM, Hsu F, Aguirre AJ, Wolpin BM, Fuchs CS, Hahn WC, Jacks T, Bhatia SN. iRGD-guided tumor-penetrating nanocomplexes for therapeutic siRNA delivery to pancreatic cancer. Mol Cancer Ther. 2018 Aug 10. pii: molcanther.1090.2017. doi: 10.1158/1535-7163.MCT-17-1090. [Epub ahead of print]. PMID:30097486.
     
  • Dayton TL, Gocheva V, Miller KM, Bhutkar A, Lewis CA, Bronson RT, Vander Heiden MG, Jacks T. Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma. Cell Metab.2018 May 31;6:6. doi: 10.1186/s40170-018-0179-2. eCollection 2018. PMID: 29854399.
     
  • Tao Z, Muzumdar MD, Detappe A, Huang X, Xu ES, Yu Y, Mouhieddine TH, Song H, Jacks T, Ghoroghchian PP. Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer. Nano Lett. 2018 Apr 11;18(4):2195-2208. doi: 10.1021/acs.nanolett.7b04043. Epub 2018 Mar 21.PMID:29533667.
     
  • Roper J, Tammela T, Akkad A, Almeqdadi M, Santos SB, Jacks T, Yilmaz ÖH. Colonoscopy-based colorectal cancer modeling in mice with CRISPR-Cas9 genome editing and organoid transplantation. Nat Protoc. 2018 Feb;13(2):217-234. doi: 10.1038/nprot.2017.136. Epub 2018 Jan 4.PMID:9300388.
     
  • Chen PY, Muzumdar MD, Dorans KJ, Robbins  R, Bhutkar A,, Del Rosario A, Mertins P, Qiao J, Schafer AC, Gertler F, Carr S, Jacks T. Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Cancer Res. 2018 Feb 15;78(4):985-1002. doi: 10.1158/0008-5472.CAN-17-2129. Epub 2017 Dec 26. PMID: 29279356.
  • Muzumdar MD, Chen PY, Dorans KJ, Chung KM, Bhutkar A, Hong E, Noll EM, Sprick MR, Trumpp A, Jacks T. Survival of pancreatic cancer cells lacking KRAS function. Nat Commun. 2017 Oct 23;8(1):1090. doi: 10.1038/s41467-017-00942-5. PMID: 29061961.
     
  • Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Sánchez-Rivera FJ, Subbaraj L, Martinez B, Bronson RT, Prigge JR, Schmidt EE, Thomas CJ, Goparaju C, Davies A, Dolgalev I, Heguy A, Allaj V, Poirier JT, Moreira AL, Rudin CM, Pass HI, Vander Heiden MG, Jacks T, Papagiannakopoulos T. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nature Med. 2017 Oct 2; doi: 10.1038/nm.4407. [Epub ahead of print] PMID: 28967920.
     
  • Lee JH, Tammela T, Hofree M, Choi J, Marjanovic ND, Han S, Canner D, Wu K, Paschini M, Bhang DH, Jacks T, Regev A, Kim CF. Anatomically and Functionally Distinct Lung Mesenchymal Populations Marked by Lgr5 and Lgr6. Cell. 2017 Sep 7;170(6):1149-1163.e12. doi: 10.1016/j.cell.2017.07.028. PMID: 28886383.
     
  • Gocheva V, Naba A, Bhutkar A, Guardia T, Miller KM, Li CM, Dayton TL, Sanchez-Rivera FJ, Kim-Kiselak C, Jailkhani N, Winslow MM, Del Rosario A, Hynes RO, Jacks T. Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):E5625-E5634. doi: 10.1073/pnas.1707054114. Epub 2017 Jun 26. PMID:28652369.
     
  • JnBaptiste CK, Gurtan AM, Thai KK, Lu V, Bhutkar A, Su MJ, Rotem A, Jacks T, Sharp PA. Corrigendum: Dicer loss and recovery induce an oncogenic switch driven by transcriptional activation of the oncofetal Imp1-3 family. Genes Dev. 2017 May 15;31(10):1066. doi: 10.1101/gad.302513.117. No abstract available. PMID: 28637695.
     
  • Tammela T, Sanchez-Rivera FJ, Cetinbas NM, Wu K, Joshi NS, Helenius K, Park Y, Azimi R, Kerper NR, Wesselhoeft RA, Gu X, Schmidt L, Cornwall-Brady M, Yilmaz ÖH, Xue W, Katajisto P, Bhutkar A, Jacks T. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature. 2017 May 18;545(7654):355-359. doi: 10.1038/nature22334. Epub 2017 May 10. PMID:28489818.
     
  • Roper J, Tammela T, Cetinbas NM, Akkad A, Roghanian A, Rickelt S, Almeqdadi M, Wu K, Oberli MA, Sánchez-Rivera F, Park YK, Liang X, Eng G, Taylor MS, Azimi R, Kedrin D, Neupane R, Beyaz S, Sicinska ET, Suarez Y, Yoo J, Chen L, Zukerberg L, Katajisto P, Deshpande V, Bass AJ, Tsichlis PN, Lees J, Langer R, Hynes RO, Chen J, Bhutkar A, Jacks T, Yilmaz ÖH. In vivo genome editing and organoid tranplantation models of colorectal cancer and metastasis. Nat Biotechnol. 2017 Jun;35(6):569-576. doi: 10.1038/nbt.3836. Epub 2017 May 1. PMID: 28459449.
     
  • JnBaptiste CK, Gurtan AM, Thai KK, Lu V, Bhutkar A, Su MJ, Rotem A, Jacks T, Sharp PA. Dicer loss and recovery induce an oncogenic switch driven by transcriptional activation of the oncofetal Imp1-3 family. Genes Dev. 2017 April 1;31(7):674-87. doi: 10.1101/gad.296301.117.PMID:28446596.

  • McFadden DG, Politi K, Bhutkar A, Chen FK, Song X, Pirun M, Santiago PM, Kim-Kiselak C, Platt JT, Lee E, Hodges E, Rosebrock AP, Bronson RT, Socci ND, Hannon GJ, Jacks T, Varmus H. Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma. Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6409-E6417.

  • Mayers JR, Torrence ME, Danai LV, Papagiannakopoulos T, Davidson SM, Bauer MR, Lau AN, Ji BW, Dixit PD, Hosios AM, Muir A, Chin CR, Freinkman E, Jacks T, Wolpin BM, Vitkup D, Vander Heiden MG. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science. 2016 Sep 9;353(6304):1161-5. doi: 10.1126/science.aaf5171.

  • Muzumdar MD, Dorans KJ, Chung KM, Robbins R, Tammela T, Gocheva V, Li CM, Jacks T. Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancer. Nat Commun. 2016 Sep 2;7:12685. doi: 10.1038/ncomms12685.

  • Papagiannakopoulos T, Bauer MR, Davidson SM, Heimann M, Subbaraj L, Bhutkar A, Bartlebaugh J, Vander Heiden MG, Jacks T. Circadian rhythm disruption promotes lung tumorigenesis. Cell Metab. 2016 Aug 9;24(2):324-31. doi: 10.1016/j.cmet.2016.07.001.

  • Masri S, Papagiannakopoulos T, Kinouchi K, Liu Y, Cervantes M, Baldi P, Jacks T, Sassone-Corsi P. Lung adenocarcinoma distally rewires hepatic circadian homeostasis. Cell. 2016 May 5;165(4):896-909. doi: 10.1016/j.cell.2016.04.039.

  • Dayton TL, Gocheva V, Miller KM, Israelsen WJ, Bhutkar A, Clish CB, Davidson SM, Luengo A, Bronson RT, Jacks T, Vander Heiden MG. Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. Genes Dev. 2016 May 1;30(9):1020-33. doi: 10.1101/gad.278549.116.

  • Akama-Garren EH, Joshi NS, Tammela T, Chang GP, Wagner BL, Lee DY, Rideout WM 3rd, Papagiannakopoulos T, Xue W, Jacks T. A modular assembly platform for rapid generation of DMA constructs. Sci Rep. 2016 Feb 18;6:16836. doi: 10.1038/srep16836.

  • Davidson SM, Papagiannakopoulos T, Olenchock BA, Heyman JE, Keibler MA, Luengo A, Bauer MR, Jha AK, O'Brien JP, Pierce KA, Gui DY, Sullivan LB, Wasylenko TM, Subbaraj L, Chin CR, Stephanopolous G, Mott BT, Jacks T, Clish CB, Vander Heiden MG. Environment impacts the metabolic dependencies of Ras-driven Non-Small Cell lung cancer. Cell Metab. 2016 Mar 8;23(3):517-28. doi: 10.1016/j.cmet.2016.01.007.

  • Dimitrova N, Gocheva V, Bhutkar A, Resnick R, Jong RM, Miller KM, Bendor J, Jacks T. Stromal expression of miR-143/145 promotes neoangiogenesis in lung cancer development. Cancer Discov. 2016 Feb;6(2):188-201. doi: 10.1158/2159-8290.CD-15-0854.

  • ​​Robles-Oteiza C, Taylor S, Yates T, Cicchini M, Lauderback B, Cashman CR, Burds AA, Winslow MM, Jacks T, Feldser DM. Recombinase-based conditional and reversible gene regulation via XTR alleles. Nat Commun. 2015 Nov 5;6:8783. doi: 10.1038/ncomms9783.

  • Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S, Sánchez-Rivera FJ, Lofgren SM, Kuschma T, Hahn SA, Vangala D, Trajkovic-Arsic M, Gupta A, Heid I, Noël PB, Braren R, Erkan M, Kleeff J, Sipos B, Sayles LC, Heikenwalder M, Heßmann E, Ellenrieder V, Esposito I, Jacks T, Bradner JE, Khatri P, Sweet-Cordero EA, Attardi LD, Schmid RM, Schneider G, Sage J, Siveke JT. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med. 2015 Oct;21(10):1163-71. doi: 10.1038/nm.3952.

  • Li CM, Gocheva V, Oudin MJ, Bhutkar A, Wang SY, Date SR, Ng SR, Whittaker CA, Bronson RT, Snyder EL, Gertler FB, Jacks T. Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes Dev. 2015 Sep 1;29(17):1850-62. doi: 10.1101/gad.267393.115.

  • Joshi NS, Akama-Garren EH, Lu Y, Lee DY, Chang GP, Li A, DuPage M, Tammela T, Kerper NR, Farago AF, Robbins R, Crowley DM, Bronson RT, Jacks T. Regulatory T Cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T Cell respsonses. Immunity. 2015 Sep 15;43(3):579-90. doi: 10.1016/j.immuni.2015.08.006.

  • Sánchez-Rivera FJ, Jacks T. Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer. 2015 Jul;15(7):387-95. doi: 10.1038/nrc3950.

  • Li Y, Park A, Mou H, Colpan C, Bizhanova A, Akama-Garren E, Joshi N, Hendrickson EA, Feldser D, Yin H, Anderson DG, Jacks T, Weng Z, Xue W. A versatile reporter system for CRISPR-mediated chromosomal rearrangements. Genome Biol. 2015 May 28;16(1):111.doi: 10.1186/s13059-015-0680-7

  • Khan OF, Zaia EW, Jhunjhunwala S, Xue W, Cai W, Yun DS, Barnes CM, Dahlman JE, Dong Y, Pelet JM, Webber MJ, Tsosie JK, Jacks TE, Langer R, Anderson DG. Dendrimer-Inspired Nanomaterials for the in Vivo Delivery of siRNA to Lung Vasculature. Nano Lett. 2015 May 13;15(5):3008-16. doi: 10.1021/nl5048972.

  • Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, Wagner BL, Rideout WM 3rd, Jakubik CT, Ham J, Edelman EJ, Ebi H, Yeo AT, Hata AN, Song Y, Patel NU, March RJ, Tam AT, Milano RJ, Boisvert JL, Hicks MA, Elmiligy S, Malstrom SE, Rivera MN, Harada H, Windle BE, Ramaswamy S, Benes CH, Jacks T, Engelman JA. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1288-96. doi: 10.1073/pnas.1411848112.

  • Gazdar AF, Savage TK, Johnson JE, Berns A, Sage J, Linnoila RI, MacPherson D, McFadden DG, Farago A, Jacks T, Travis WD, Brambilla E. The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol. 2015 Apr;10(4):553-64. doi: 10.1097/JTO
  • Sánchez-Rivera FJ, Papagiannakopoulos T, Romero R, Tammela T, Bauer MR, Bhutkar A, Joshi NS, Subbaraj L, Bronson RT, Xue W, Jacks T. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature. 2014 Dec 18;516(7531):428-31. doi: 10.1038/nature13906. Epub 2014 Oct 22.
     
  • Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi NS, Cai W, Yang G, Bronson R, Crowley DG, Zhang F, Anderson DG, Sharp PA, Jacks T. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature. 2014 Oct 16;514(7522):380-4. doi: 10.1038/nature13589. Epub 2014 Aug 6.
     
  • Xue W, Dahlman JE, Tammela T, Khan OF, Sood S, Dave A, Cai W, Chirino LM, Yang GR, Bronson R, Crowley DG, Sahay G, Schroeder A, Langer R, Anderson DG, Jacks T. Small RNA combination therapy for lung cancer. Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):E3553-61. doi: 10.1073/pnas.1412686111. Epub 2014 Aug 11.
     
  • Diane D. Shao, Wen Xue, Elsa B. Krall, Arjun Bhutkar, Federica Piccioni, Xiaoxing Wang, Anna C. Schinzel, Sabina Sood, Joseph Rosenbluh, Jong W. Kim, Yaara Zwang, Thomas M. Roberts, David E. Root, Tyler Jacks and William C. Hahn. 2014. KRAS and YAP1 Converge to Regulate EMT and Tumor Survival. Cell. 2014 Jul 3. doi: 10.1016/j.cell.2014.06.004. Epub 2014 Jun 19.
     
  • Chiou SH, Kim-Kiselak C, Risca VI, Heimann MK, Chuang CH, Burds AA, Greenleaf WJ, Jacks TE, Feldser DM, Winslow MM. 2014. A conditional system to specifically link disruption of protein-coding function with reporter expression in mice. Cell Rep. 2014 Jun 26;7(6):2078-86. doi: 10.1016/j.celrep.2014.05.031.
     
  • Karsli-Uzunbas G, Guo JY, Price SM, Teng X, Laddha SV, Khor S, Kalaany NY, Jacks T, Chan CS, Rabinowitz JD, White E. 2014. Autophagy is Required for Glucose Homeostasis and Lung Tumor Maintenance. Cancer Discov. 2014 May 29. pii: CD-14-0363. [Epub ahead of print]
     
  • Dimitrova, N., Zamudio, J.R., Jong R. M., Soukup, D., Resnick, R., Sarma, K., Ward, A.J., Raj, A., Lee, J., Sharp, P.A., Jacks, T. 2014. LincRNA-p21 activates p21 in cis to promote Polycomb target gene expression and to enforce the G1/S checkpoint. Molecular Cell, 2014 Jun 5;54(5):777-90. doi: 10.1016/j.molcel.2014.04.025. 
     
  • McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, McMahon M, Sadow PM, Jacks T. 2014. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):E1600-9. doi: 10.1073/pnas.1404357111. 
     
  • Gierut JJ, Jacks TE, Haigis KM. 2014. Whole-mount x-gal staining of mouse tissues. Cold Spring Harb Protoc. 2014 Apr 1;2014(4):417-9. doi: 10.1101/pdb.prot073452.
     
  • Gierut JJ, Jacks TE, Haigis KM. 2014. Strategies to achieve conditional gene mutation in mice. Cold Spring Harb Protoc. 2014 Apr 1;2014(4):339-49. doi: 10.1101/pdb.top069807.
     
  • Yin H, Xue W, Chen S, Bogorad RL, Benedetti E, Grompe M, Koteliansky V, Sharp PA, Jacks T, Anderson DG. 2014. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. 2014 Jun;32(6):551-3. doi: 10.1038/nbt.2884.
     
  • David G. McFadden, Thales Papagiannakopoulos, Amaro Taylor-Weiner, Chip Stewart, Scott L. Carter, Kristian Cibulskis, Arjun Bhutkar, Aaron McKenna, Alison Dooley, Amanda Vernon, Carrie Sougnez, Scott Malstrom, Megan Heimann, Jennifer Park, Frances Chen, Anna F. Farago, Talya Dayton, Erica Shefler, Stacey Gabriel, Gad Getz, Tyler Jacks. 2014. Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing. Cell. 156(6):1298–1311.
     
  • Gierut JJ, Jacks TE, Haigis KM. 2014. In vivo delivery of lenti-cre or adeno-cre into mice using intranasal instillation. Cold Spring Harb Protoc. 2014 Mar 1;2014(3):307-9. doi: 10.1101/pdb.prot073445.
     
  • Gierut JJ, Jacks TE, Haigis KM. 2014. Producing and concentrating lenti-cre for mouse infections. Cold Spring Harb Protoc. 2014 Mar 1;2014(3):304-6. doi: 10.1101/pdb.prot073437.
  • Vanden Borre P, McFadden DG, Gunda V, Sadow PM, Varmeh S, Bernasconi MJ, Jacks T, Parangi S. 2014. The Next Generation of Orthotopic Thyroid Cancer Models: Immunocompetent Orthotopic Mouse Models of BRAF^V600E-Positive Papillary and Anaplastic Thyroid Carcinoma. Thyroid. 2014 Apr;24(4):705-14. doi: 10.1089/thy.2013.0483.
     
  • Morandell S, Reinhardt HC, Cannell IG, Kim JS, Ruf DM, Mitra T, Couvillon AD, Jacks T, Yaffe MB. 2013. A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response In Vivo. Cell Rep. 27;5(4):868-77.
     
  • Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, DePinho RA, Clish CB, Jacks T, Kibbey RG, Wulf GM, Di Vizio D, Mills GB, Cantley LC, Vander Heiden MG. 2013. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell. 10;155(2):397-409.
     
  • Li CM, Chen G, Dayton TL, Kim-Kiselak C, Hoersch S, Whittaker CA, Bronson RT, Beer DG, Winslow MM, Jacks T. 2013. Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. Genes Dev. 27(14):1557-67.
     
  • Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, Chen G, Price S, Lu W, Teng X, Snyder E, Santanam U, Dipaola RS, Jacks T, Rabinowitz JD, White E. 2013. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev. 27(13):1447-61.
     
  • Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K. 2013. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov. 3(9):993-1001.
     
  • Curry NL, Mino-Kenudson M, Oliver TG, Yilmaz OH, Yilmaz VO, Moon JY, Jacks T, Sabatini DM, Kalaany NY. 2013. Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. Cancer Discov. 3(8):908-21.
     
  • Physical Sciences - Oncology Centers Network, Agus DB, Alexander JF, Arap W, Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC, Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P, Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J, Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S, Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, Hielscher A, Hillis WD, Holland EC, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE, Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P, Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, Lloyd MC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F, Mumenthaler SM, Nandakumar V, O'Halloran TV, Oh S, Pasqualini R, Paszek MJ, Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P, Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, Tormoen GW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH. 2013. A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep. 3:1449.
     
  • Byun S, Son S, Amodei D, Cermak N, Shaw J, Kang JH, Hecht VC, Winslow MM, Jacks T, Mallick P, Manalis SR. 2013. Characterizing deformability and surface friction of cancer cells. Proc Natl Acad Sci U S A. 7;110(19):7580-5.
     
  • Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, Crowley D, Whittaker CA, Meyerson M, Kimura S, Jacks T. 2013. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell. 50(2):185-99.
     
  • Joshi NS, Jacks T. 2013. Immunology. Guilty by association. Science. 8;339(6124):1160-1.
     
  • DuPage M, Jacks T. 2013. Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr Opin Immunol. 25(2):192-9.
     
  • Watanabe H, Francis JM, Woo MS, Etemad B, Lin W, Fries DF, Peng S, Snyder EL, Tata PR, Izzo F, Schinzel AC, Cho J, Hammerman PS, Verhaak RG, Hahn WC, Rajagopal J, Jacks T, Meyerson M. 2013. Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes Dev.15;27(2):197-210.
  • Reticker-Flynn NE, Malta DF, Winslow MM, Lamar JM, Xu MJ, Underhill GH, Hynes RO, Jacks TE, Bhatia SN. 2012. A combinatorial extracellular matrix platform identifies cell-extracellular matrix interactions that correlate with metastasis. Nat Commun. 2012;3:1122.
  • Ravi A, Gurtan AM, Kumar MS, Bhutkar A, Chin C, Lu V, Lees JA, Jacks T, Sharp PA. 2012. Proliferation and Tumorigenesis of a Murine Sarcoma Cell Line in the Absence of DICER1. Cancer Cell, 21(6):848-855.
  • Farago AF, Snyder EL, Jacks T. 2012.SnapShot: Lung cancer models. Cell, 149(1):246-246.
  • DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. 2012. Expression of tumour-specific antigens underlies cancer immunoediting. Nature, 482(7385):405-409.
  • Itzkovitz S, Blat IC, Jacks T, Clevers H, van Oudenaarden A. 2012. Optimality in the development of intestinal crypts. Cell, 148(3):608-619.
  • Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG. 2011. Treating metastatic cancer with nanotechnology. Nat Rev Cancer, Dec 23;12(1):39-50.
  • Itzkovitz S, Lyubimova A, Blat IC, Maynard M, van Es J, Lees J, Jacks T, Clevers H, van Oudenaarden A. 2011. Single-molecule transcript counting of stem-cell markers in the mouse intestine. Nat Cell Biol. 14(1):106-114. PMCID: PMC3292866.
  • Oliver TG, Meylan E, Chang GP, Xue W, Burke JR, Humpton TJ, Hubbard D, Bhutkar A, Jacks T. 2011. Caspase-2-Mediated Cleavage of Mdm2 Creates a p53-Induced Positive Feedback Loop. Molecular Cell, 43(1):57-71. PMCID: PMC3160283.
  • Xue W, Meylan E, Oliver TG, Feldser DM, Winslow MM, Bronson R, Jacks T. 2011. Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discovery, 1(3):236-47. PMCID: PMC3160630.
  • Dooley AL, Winslow MM, Chiang DY, Banerji S, Stransky N, Dayton TL, Snyder EL, Senna S, Whittaker CA, Bronson RT, Crowley D, Barretina J, Garraway L, Meyerson M, Jacks T. 2011. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev., 25(14):1470-1475. PMCID: PMC3143937.
  • Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage M, Whittaker CA, Hoersch S, Yoon S, Crowley D, Bronson RT, Chiang DY, Meyerson M, and Jacks T. 2011. Suppression of Lung Adenocarcinoma Progression by Nkx2-1. Nature, 473(7345):101-104. PMCID: PMC3088778.
  • Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, Lewis TA, Maglathin RL, Tolliday N, Jacks T. 2011. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A, 08(21):8773-8778. PMCID: PMC3102385.
  • Young NP, Crowley D and Jacks T. 2011. Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Research, 71(11):4040-4047. PMCID: PMC3160277.
  • DuPage M, Cheung A, Mazumdar , Winslow MM, Bronson R, Schmidt LM, Crowley D, Chen J, and Jacks T. 2011. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell, 19(1):72-85. PMCID: PMC3069809.
  • Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, Randall McAuley J, Poveromo L, Kutok JL, Galili N, Raza A, Attar E, Gilliland DG, Jacks T, Ebert BL. 2011. Coordinate loss of a microRNA and protein coding gene cooperate in the pathogenesis of 5q- syndrome. Blood, Oct 27;118(17):4666-73. doi: 10.1182/blood-2010-12-324715. Epub 2011 Aug 26.
  • To MD, Quigley D, Mao JH, Del Rosario R, Hsu J, Hodgson JG, Jacks T, Balmain A. 2011. Progressive genomic instability in the FVB/KrasLA2 mouse model of lung cancer. Mol Cancer Res, Oct;9(10):1339-45. doi: 10.1158/1541-7786.MCR-11-0219. Epub 2011 Aug 1.
  • Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K. 2011. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. Blood, 2011 Feb 10;117(6):2022-32. doi: 10.1182/blood-2010-04-280750. Epub 2010 Dec 16. PMCID: PMC3056645.
  • Cellurale C, Sabio G, Kennedy NJ, Das M, Barlow M, Sandy P, Jacks T, Davis RJ. 2011. Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. Mol Cell Biol., 31(7):1565-76. PMCID: PMC3135291.
  • Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, and Jacks T. 2010. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature, 468 (7323):572-575. PMCID: PMC3003305.
  • Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng M, Subramanian A, Mu D, Powers S, Crowley D, Bronson RT, Whittaker CA, Bhutkar A, Lippard SJ, Golub T, Thomale J, Jacks T, Sweet-Cordero EA. 2010. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes and Development, 24(8):837-852. PMCID: PMC2854397.
  • Young NP, Jacks T. 2010. Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc Natl Acad Sci U S A., 107(22):10184-10189. PMCID: PMC2890471.
  • Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT. 2010. Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci U S A, 107(48):20786-20791. PMCID: PMC2996428.
  • Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M, Attardi LD, Regev A, Lander ES, Jacks T, Rinn JL. 2010. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell, 142(3):409-419. PMCID: PMC2956184.
  • Mazumdar J, Hickey MM, Pant DK, Durham AC, Sweet-Cordero A, Vachani A, Jacks T, Chodosh LA, Kissil JL, Simon MC, Keith B. 2010. HIF-2alpha deletion promotes Kras-driven lung tumor development. Proc Natl Acad Sci U S A., 107(32):14182-14187. PMCID: PMC2922515.
  • Lazzara MJ, Lane K, Chan R, Jasper PJ, Yaffe MB, Sorger PK, Jacks T, Neel BG, Lauffenburger DA. 2010. IMPAIRED SHP2-MEDIATED ERK ACTIVATION CONTRIBUTES TO GEFITINIB SENSITIVITY OF LUNG CANCER CELLS WITH EGFR-ACTIVATING MUTATIONS. Cancer Research, 70(9):3843-3850. PMCID: PMC2897160.
  • Kirsch DG, Santiago PM, di Tomasso E, Sullivan JM, Hou WS, Dayton T, Jeffords LB, Sodha P, Mercer K, Cohen R, Takeuchi O, Korsmeyer SJ, Bronson R, Kim CF, Haigis KM, Jain RK, Jacks T. 2010. p53 Controls Radiation-induced Gastrointestinal Syndrome in Mice Independent of Apoptosis. Science, 327(5965):593-596. PMCID: PMC2897160.
  • Cheung AF, Carter AM, Kostova KK, Woodruff JF, Crowley D, Bronson RT, Haigis KM, Jacks T. 2010. Complete deletion of Apc results in severe polyposis in mice. Oncogene, 29(12):1857-1864. PMCID: PMC2990498.
  • Zhou Y, Rideout WM 3rd, Zi T, Bressel A, Reddypalli S, Rancourt R, Woo JK, Horner JW, Chin L, Chiu MI, Bosenberg M, Jacks T, Clark SC, Depinho RA, Robinson MO, Heyer J. 2010. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnology, 28(1):71-78.
  • Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T. 2009. Requirement for NF-kB signaling in a mouse model of lung adenocarcinoma. Nature, 462(7269):104-107. PMCID: PMC2780341
  • Kirsch DG, Grimm J, Guimaraes AR, Wojtkiewicz GR, Perez BA, Santiago PM, Anthony NK, Forbes T, Doppke K, Weissleder R, Jacks T. 2009. Imaging Primary Lung Cancers in Mice to Study Radiation Biology. International Journal of Radiation Oncology, Biology, Physics, 76(4):973-977. PMCID: PMC2847457.
  • Kumar MS, P RE, Chen CY, esterLane K, Chin C, Lu J, Kirsch DG, Golub TR, Jacks T . 2009. Dicer1 functions as a haploinsufficient tumor suppressor. Genes and Development, 23 (23), 2700-2705. PMCID: PMC2788328
  • Gidekel Friedlander SY, Chu GC, Snyder EL, Girnius N, Dibelius G, Crowley D, Vasile E, DePinho RA, Jacks T. 2009. Context-dependent transformation of adult pancreatic cells by oncogenic K-ras. Cancer Cell, 16(5):379-389. PMCID: PMC3048064
  • Mito JK, Riedel RF, Dodd L, Lahat G, Lazar AJ, Dodd RD, Stangenberg L, Eward WC, Hornicek FJ, Yoon SS, Brigman BE, Jacks T, Lev D, Mukherjee S, Kirsch DG. 2009. Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One, 4(11):e8075. PMCID: PMC2779485
  • Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC. 2009. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature, 462(7269):108-112. PMCID: PMC2783335
  • Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA. 2009. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell, 16(1):21-32. PMCID: PMC2752826
  • Yoon SS, Stangenberg L, Lee YJ, Rothrock C, Dreyfuss JM, Baek KH, Waterman PR, Nielsen GP, Weissleder R, Mahmood U, Park PJ, Jacks T, Dodd RD, Fisher CJ, Ryeom S, Kirsch DG. 2009. Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. Int J Radiat Oncol Biol Phys, 74(4):1207-1216. PMCID: PMC2733223
  • Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG. 2009. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell, 137(5):821-834.
  • Dupage M*, Dooley AL*, Jacks T. 2009. Conditional mouse lung tumor models using adenoviral or lentiviral delivery of Cre recombinase. Nature protocols, 4(7): 1064-1072. PMCID: PMC2757265
  • Lin YL, Sengupta S, Gurdziel K, Bell GW, Jacks T, Flores ER. 2009. p63 and p73 transcriptionally regulate genes involved in DNA repair.. PLoS Genet. 2009 Oct;5(10):e1000680. PMCID: PMC2752189
  • Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, Cabili MN, Jaenisch R, Mikkelsen TS, Jacks T, Hacohen N, Bernstein BE, Kellis M, Regev A, Rinn JL, Lander ES. 2009. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature, 458(7235), 223-227. PMCID: PMC2754849
  • Cheung AF, Dupage MJP, Dong HK, Chen J, Jacks T. 2008. Regulated expression of a tumor-associated antigen reveals multiple levels of T cell tolerance in a mouse model of lung cancer. Cancer Research, 68(22):9459-9468. PMCID: PMC2597052
  • Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, McAllister SS, Jacks T, Weinberg RA. 2008. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell, 134, 62-73. PMC in progress
  • Ventura, A., Young, A., Winslow, M., Lintault, L., Meissner, A., Erkeland, S., Newman, J., Bronson, R., Crowley, D., Stone, J., Jaenisch, R., Sharp, P., Jacks T. 2008. Targeted deletion reveals essential and overlapping functions of the miR-17~92 family of miRNA clusters. Cell, 132, 875-886. PMCID:PMC2323338
  • Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, and Jacks T. 2008. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc.Natl.Acad.Sci, 105, 3903-3908. PMCID: PMC2268826
  • Nolen-Walston RD, Kim CF, Mazan MR, Ingenito EP, Gruntman AM, Tsai L, Boston R, Woolfenden AE, Jacks T, Hoffman AM. 2008. Cellular kinetics and modeling of bronchioalveolar stem cell response during lung regeneration. Am J Physiol Lung Cell Mol Physiol, 294(6): L1158-65. PMCID:PMC2593913
  • Zhang Q, Menon R, Deutsch EW, Pitteri SJ, Faca VM, Wang H, Newcomb LF, Depinho RA, Bardeesy N, Dinulescu D, Hung KE, Kucherlapati R, Jacks T, Politi K, Aebersold R, Omenn GS, States DJ, Hanash SM. 2008. A mouse plasma peptide atlas as a resource for disease proteomics. Genome Biol, 9(6):R93. PMCID:PMC2481425
  • Haigis, K.M., Kendall, K.R., Wang Y., Cheung, A, Haigis, M.C, Glickman J.N., Niwa-Kawakita, M., Sweet-Cordero, A., Sebolt-Leopold J., Shannon, K.M., Settleman J., Giovannini M., and Jacks T. 2008. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nature Genetics,40, 600-608. PMCID:PMC2410301
  • Kissil JL, Walmsley MJ, Hanlon L, Haigis KM, Bender Kim CF, Sweet-Cordero A, Eckman MS, Tuveson DA, Capobianco AJ, Tybulewicz VL, Jacks T. 2007. Requirement for Rac1 in a K-ras induced lung cancer in the mouse. Cancer Research, 67(17):8089-8094.
  • Pandey J, Umphress S, Kang Y, Angdisen J, Naumova A, Mercer K, Jacks T, Jakowlew SB. 2007. Modulation of tumor induction and progression of oncogenic K-ras positive tumors in the presence of TGF-{beta}1 haploinsufficiency. Carcinogenesis, 28, 2589-2596
  • Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, Young NP, Nielsen GP, Quade BJ, Chaber CJ, Schultz CP, Takeuchi O, Bronson RT, Crowley D, Korsmeyer SJ, Yoon SS, Hornicek FJ, Weissleder R, Jacks T. 2007. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nature Medicine,13(8):992-997.
  • Wijnhoven SW, Speksnijder EN, Liu X, Zwart E, vanOostrom CT, Beems RB, Hoogervorst EM, Schaap MM, Attardi LD, Jacks T, van Steeg H, Jonkers J, de Vries A. 2007. Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. Cancer Research, 67(10):4648-4656.
  • Kumar MS, Lu j, Mercer KL, Golub, TR and Jacks T. 2007. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature Genetics,39(5):673-677.
  • Shaw AT, Meissner A, Dowdle JA, Crowley D, Magendantz M, Ouyang C, Parisi T, Rajagopal J, Blank LJ, Bronson RT, Stone JR, Tuveson DA, Jaenisch, R, and Jacks, T. 2007. Sprouty-2 Regulates Oncogenic K-ras in Lung Development and Tumorigenesis. Genes & Development, 21(6):694-707.
  • McLaughlin ME, Kruger GM, Slocum KL, Crowley D, Michaud NA, Huang J, Magendantz M, and Jacks T. 2007. The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion. PNAS,104(9):3261-3266.
  • Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R and Jacks T. 2007. Restoration of p53 function leads to tumor regression in vivo. Nature 445, 661-665
  • See also Comment by Sharpless and DePinho, Nature 445, 606-607.
  • Zhang J, Liu Y, Beard C, Tuveson DA, Jaenisch R, Jacks TE, Lodish HF. 2007. Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways. Blood 109(12):5238-5241.
  • Macpherson D, Conkrite K, Tam M, Mukai S, Mu D, and Jacks T. 2007. Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. EMBO J, 26, 784 - 794.
  • Keller JW, Haigis KM, Franklin JL, Whitehead RH, Jacks T, Coffey RJ. 2006.Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS: gelsolin complex. Oncogene, 26(21):3051-3059.
  • Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, Coven S, McMahon K, Kovach S, Feng Y, Yaffe MB, Jacks T, Housman D.2006.ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res., 66(15):7473-7481.
  • To MD, Perez-Losada J, Mao JH, Hsu J, Jacks T, Balmain A.2006.A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2(LA2) mice. Nature Genetics, 38(8):926-930.
  • Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K.2006.Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. Blood, 108(6):2041-2044.
  • Daikoku T, Tranguch S, Trofimova IN, Dinulescu DM, Jacks T, Nikitin AY, Connolly DC, Dey SK. 2006.Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Research, 66(5):2527-2531.
  • Tuveson DA, Zhu L, Gopinathan A,Willis NA, Kachatrian L,Grochow R, Pin CL, Mitin NY, Taparowsky EJ,
  • Gimotty PA, Hruban RH, Jacks T, Konieczny SF. 2006.Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma. Cancer Research, 66(1):242-247.
  • Sweet-Cordero A, Tseng GC, You H, Douglass M, Huey B, Albertson D, Jacks T. 2006.Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes Cancer, 45(4):338-48.
  • Haigis K, Sage J, Glickman J, Shafer S, Jacks T. 2005. The related retinoblastoma (pRb) and p130 proteins cooperate to regulate homeostasis in the intestinal epithelium. J Biol Chem., 281(1):638-47
  • Chao RC, Pyzel U, Fridlyand J, Kuo YM, Teel L, Haaga J, Borowsky A, Horvai A, Kogan SC, Bonifas J, Huey B, Jacks TE, Albertson DG, Shannon KM. 2005. Therapy-induced malignant neoplasms in Nf1 mutant mice . Cancer Cell, 4:337-348.
  • Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T. 2005. The Differential Effects of Mutant p53 Alleles on Advanced Murine Lung Cancer . Cancer Research, 65(22)10280-10287.
  • Grimm J, Kirsch DG, Windsor SD, Kim CF, Santiago PM, Ntziachristos V, Jacks T, Weissleder R.. 2005. Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. PNAS, 102(40):14404-14409
  • Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeg H, de Vries A. 2005. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development.Cancer Res, 65(18):8166-8173.
  • Sandy P, Ventura A, Jacks T. 2005. Mammalian RNAi: a practical guide.Biotechniques, 39(2):215-224.
  • Kuns R, Kissil JL, Newsham IF, Jacks T, Gutmann DH, Sherman LS. 2005. Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation. Oncogene, 24(43):6502-15
  • Shaw AT, Kirsch DG, Jacks T. 2005. Future of early detection of lung cancer: the role of mouse models. . Clin Cancer Res. 11(13 Pt 2):4999s-5003s
  • Kim CF ,Jackson EL ,Woolfenden AE ,Lawrence S ,Babar I ,Vogel S ,Crowley D ,Bronson RT ,Jacks T .2005. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell. 121(6):823-835.
  • See also: "Stem Cells for Lung Cancer?" by Anton Berns, Cell,121(6), 811-813
  • Lu J ,Getz G ,Miska EA ,Alvarez-Saavedra E ,Lamb J ,Peck D ,Sweet-Cordero A ,Ebert BL ,Mak RH ,Ferrando AA ,Downing JR ,Jacks T ,Horvitz HR ,Golub TR .2005. MicroRNA expression profiles classify human cancers. Nature. 435(7043):834-838.
  • Bono P ,Cordero E ,Johnson K ,Borowsky M ,Ramesh V ,Jacks T ,Hynes RO . 2005. Layilin, a cell surface hyaluronan receptor, interacts with merlin and radixin. Exp Cell Res. 2005 [Epub ahead of print]
  • Hoogervorst EM ,Bruins W ,Zwart E ,van Oostrom CT ,van den Aardweg GJ ,Beems RB ,van den Berg J ,Jacks T ,van Steeg H ,de Vries A . 2005. Lack of p53 Ser389 phosphorylation predisposes mice to develop 2-acetylaminofluorene-induced bladder tumors but not ionizing radiation-induced lymphomas. . Cancer Res. 65(9):3610-3616.
  • Elsa R. Flores, Shomit Sengupta, John B. Miller, Jamie Newman, Roderick Bronson, Denise Crowley, Annie Yang, Frank McKeon, Tyler Jacks. 2005. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell, (4):363-373
  • Alejandro Sweet-Cordero, Sayan Mukherjee, Aravind Subramanian, Han You, Jeff
  • Roix, Christine Ladd, Jill Mesirov, Todd R. Golub, Tyler Jacks. 2005. An oncogenic Kras expression signature identified by cross-species gene expression analysis. Nature Genetics, 37 (1), 48-55
    Gene expression data available here
  • See also article by Thomas G Graeber & Charles L Sawyers: "Cross-species comparisons of cancer signaling", Nature Genetics, 37 (1), 7 - 8 (2005)
  • Daniela M. Dinulescu, Tan A. Ince, Bradley J. Quade, Sarah A. Shafer, Denise Crowley, Tyler Jacks. 2005. Role of K-ras and Pten in the Development of Mouse Models of Endometriosis and Endometrioid Ovarian Cancer. Nature Medicine, 11 (1), 63 - 70.
  • See also article by Martin M Matzuk: "Gynecologic diseases get their genes", Nature Medicine, 11 (1), 24-26 (2005)
  • Kenneth P. Olive, David A. Tuveson, Zachary C. Ruhe, Bob Yin, Nicholas A. Willis, Roderick T. Bronson, Denise Crowley, Tyler Jacks. 2004. Mutant p53 Gain-of-Function in Two Mouse Models of Li-Fraumeni Syndrome. Cell,119 (6), 847-860.
  • See also review in: Cell, 120 (1) 7-10 (2005).
  • Spike BT, Dirlam A, Dibling BC, Marvin J, Williams BO, Jacks T, Macleod KF. 2004. The Rb tumor suppressor is required for stress erythropoiesis. EMBO J., 23(21):4319-4329.
  • Bruins W, Zwart E, Attardi LD, Iwakuma T, Hoogervorst EM, Beems RB, Miranda B, van Oostrom CT, van den Berg J, van den Aardweg GJ, Lozano G, van Steeg H, Jacks T, de Vries A. 2004. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol. 20:8884-8894.
  • Iwakuma T, Parant JM, Fasulo M, Zwart E, Jacks T, De Vries A, Lozano G. 2004. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice. Oncogene, 23(46):7644-7650.
  • MacPherson D, Kim J, Kim T, Rhee BK, Van Oostrom CT, DiTullio RA, Venere M, Halazonetis TD, Bronson R, De Vries A, Fleming M, Jacks T. 2004. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J. 23(18):3689-3699.
  • Reilly KM, Tuskan RG, Christy E, Loisel DA, Ledger J, Bronson RT, Smith CD, Tsang S, Munroe DJ, Jacks T. 2004. Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. PNAS U S A. 101(35):13008-13013.
  • Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L, Jaenisch R, Jacks T. 2004. Cre-lox-regulated conditional RNA interference from transgenes. PNAS (101):10380-10385.
  • MacPherson D, Sage J, Kim T, Ho D, McLaughlin ME, Jacks T. 2004. Cell type-specific effects of Rb deletion in the murine retina. . Genes Dev.18(14):1681-1694.
  • Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA, Wang L, Bronson RT, Orkin SH, DePinho RA, Jacks T. 2004. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (4):375-387.
  • Mayhew CN, Perkin LM, Zhang X, Sage J, Jacks T, Knudsen ES. 2004. Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. Oncogene 23(23):4107-4120.
  • Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, Dixon D, Fraire AE, Gabrielson EW, Gunning WT, Haines DC, Kaufman MH, Linnoila RI, Maronpot RR, Rabson AS, Reddick RL, Rehm S, Rozengurt N, Schuller HM, Shmidt EN, Travis WD, Ward JM, Jacks T. 2004. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res. 64(7):2307-2316.
  • Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, Johnson L, Akashi K, Tuveson DA, Jacks T, Gilliland DG. 2004. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 113(4):528-538.
  • Attardi LD, de Vries A, Jacks T. 2004. Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. Oncogene 23(4):973-80.
  • Bosco EE, Mayhew CN, Hennigan RF, Sage J, Jacks T, Knudsen ES.2004. RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Res. 2(1):25-34.
  • Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM. 2004. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A. 101(2):597-602.
  • Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 4(6):437-50
  • Reczek EE, Flores ER, Tsay AS, Attardi LD, Jacks T. 2003 Multiple response elements and differential p53 binding control Perp expression during apoptosis. Mol Cancer Res.1(14):1048-1057.
  • Karlseder J, Kachatrian L, Takai H, Mercer K, Hingorani S, Jacks T, de Lange T.2003 Targeted deletion reveals an essential function for the telomere length regulator Trf1. Mol Cell Biol.23(18):6533-6541.
  • Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. 2003. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell. 2003 Oct;12(4):841-9.
  • Balsitis SJ, Sage J, Duensing S, Munger K, Jacks T, Lambert PF.2003. Recapitulation of the Effects of the Human Papillomavirus Type 16 E7 Oncogene on Mouse Epithelium by Somatic Rb Deletion and Detection of pRb-Independent Effects of E7 In Vivo. Mol Cell Biol. Dec 15;23(24):9094-9103.
  • Ihrie RA, Reczek E, Horner JS, Khachatrian L, Sage J, Jacks T, Attardi LD 2003. Perp Is a Mediator of p53-Dependent Apoptosis in Diverse Cell Types.Curr Biol. Nov 11;13(22):1985-90.
  • Minna JD, Kurie JM, Jacks T. 2003. A big step in the study of small cell lung cancer.Cancer Cell. Sep;4(3):163-6.
  • Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T. 2003. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature. Jul 10;424(6945):223-8.
  • McLaughlin ME, Jacks T. 2003. Progesterone receptor expression in neurofibromas. Cancer Res. Feb 15;63(4):752-5.
  • Cichowski K, Santiago S, Jardim M, Johnson BW, Jacks T. 2003. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor.Genes Dev. Feb 15;17(4):449-54.
  • MacPherson D, Sage J, Crowley D, Trumpp A, Bronson RT, Jacks T. 2003. Conditional mutation of Rb causes cell cycle defects without apoptosis in the central nervous system. Mol Cell Biol. Feb;23(3):1044-53.
  • Tsai KY, MacPherson D, Rubinson DA, Nikitin AY, Bronson R, Mercer KL, Crowley D, Jacks T. 2002. ARF mutation accelerates pituitary tumor development in Rb+/- mice. Proc Natl Acad Sci U S A. Dec 24;99(26):16865-70.
  • Lee HY, Suh YA, Lee JI, Hassan KA, Mao L, Force T, Gilbert BE, Jacks T, Kurie JM. 2002. Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. Clin Cancer Res. Sep;8(9):2970-5.
  • Johnson KC, Kissil JL, Fry JL, Jacks T. 2002. Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. Oncogene. Sep 5;21(39):5990-7.
  • Klappacher GW, Lunyak VV, Sykes DB, Sawka-Verhelle D, Sage J, Brard G, Ngo SD, Gangadharan D, Jacks T, Kamps MP, Rose DW, Rosenfeld MG, Glass CK. 2002. An induced Ets repressor complex regulates growth arrest during terminal macrophage differentiation.Cell.Apr 19;109(2):169-80.
  • Yang H, Williams BO, Hinds PW, Shih TS, Jacks T, Bronson RT, Livingston DM. 2002. Tumor suppression by a severely truncated species of retinoblastoma protein.Mol Cell Biol.May;22(9):3103-10.
  • Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, Jacks T. 2002. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature.Apr 4;416(6880):560-4.
  • de Vries A, Flores ER, Miranda B, Hsieh HM, van Oostrom CT, Sage J, Jacks T. 2002. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci U S A. Mar 5;99(5):2948-53.
  • Kim TJ, Cariappa A, Iacomini J, Tang M, Shih S, Bernards A, Jacks T, Pillai S. 2002. Defective proliferative responses in B lymphocytes and thymocytes that lack neurofibromin.Mol Immunol. Feb;38(9):701-8.
  • Tsai KY, MacPherson D, Rubinson DA, Crowley D, Jacks T. 2002. ARF is not required for apoptosis in Rb mutant mouse embryos. Curr Biol. 2002 12(2):159-63.
  • Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, Ohno M, Kucherlapati R, Jacks T, Silva AJ. 2002. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature. 415(6871):526-30.
  • Kissil JL, Johnson KC, Eckman MS, Jacks T. 2002. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem. Mar 22;277(12):10394-9.
  • Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15(24):3243-8.
  • Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, O'Bryan JP, Gupta V, Ratner N, Der CJ, Jacks T, McClatchey AI. 2001. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell. 1(1):63-72.
  • Geng Y, Yu Q, Whoriskey W, Dick F, Tsai KY, Ford HL, Biswas DK, Pardee AB, Amati B, Jacks T, Richardson A, Dyson N, Sicinski P. 2001. Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proc Natl Acad Sci U S A.98(23):13138-43.
  • Zhang Z, Wang Y, Vikis HG, Johnson L, Liu G, Li J, Anderson MW, Sills RC, Hong HL, Devereux TR, Jacks T, Guan KL, You M. 2001. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet. 29(1):25-33.
  • Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD. 2001. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 16;20(36):5054-8.
  • Lipinski MM, Macleod KF, Williams BO, Mullaney TL, Crowley D, Jacks T. 2001. Cell-autonomous and non-cell-autonomous functions of the Rb tumor suppressor in developing central nervous system. EMBO J. 2;20(13):3402-13.
  • Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. 2001. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 410(6832):1111-6.
  • Sage J, Mulligan GJ, Attardi LD, Miller A, Chen S, Williams B, Theodorou E, Jacks T. 2000. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev.14(23):3037-50.
  • Wang Y, Hayward SW, Donjacour AA, Young P, Jacks T, Sage J, Dahiya R, Cardiff RD, Day ML, Cunha GR. 2000. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res. 60(21):6008-17.
  • Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH, Kaelin WG Jr. 2000. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 407(6804):645-8.
  • Boyd SD, Tsai KY, Jacks T. 2000. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat Cell Biol. 2(9):563-8.
  • Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. 2000. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet. 26(1):109-13.
  • Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO. 2000. Cell cycle inhibition by the anti- angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci USA.;97(12):6427-32.
  • Attardi LD, Reczek EE, Cosmas C, Demicco EG, McCurrach ME, Lowe SW, Jacks T. 2000. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev. 14(6):704-18.
  • Birnbaum RA, O'Marcaigh A, Wardak Z, Zhang YY, Dranoff G, Jacks T, Clapp DW, Shannon KM. 2000. Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol Cell. 5(1):189-95.
  • Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, Bronson RT, Jacks T. 1999. Mouse models of tumor development in neurofibromatosis type 1. Science. 286(5447):2172-6.
  • Mahgoub N, Taylor BR, Gratiot M, Kohl NE, Gibbs JB, Jacks T, Shannon KM. 1999. In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Blood. 94(7):2469-76.
  • Mahgoub N, Taylor BR, Le Beau MM, Gratiot M, Carlson KM, Atwater SK, Jacks T, Shannon KM. 1999. Myeloid malignancies induced by alkylating agents in Nf1 mice. Blood. 93(11):3617-23.
  • Zhou X, Wong S, Walter J, Jacks T, Eisen HN. 1999. Increased generation of CD8+ T cell clones in p53 mutant mice. J Immunol. 162(7):3957-60.
  • Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA. 1999. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci U S A. 96(3):1002-7.
  • Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T. 1998. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol Cell. 2(3):293-304.
  • Xu Y, Yang EM, Brugarolas J, Jacks T, Baltimore D. 1998. Involvement of p53 and p21 in cellular defects and tumorigenesis in Atm-/- mice. Mol Cell Biol. 18(7):4385-90.
  • Zhang YY, Vik TA, Ryder JW, Srour EF, Jacks T, Shannon K, Clapp DW. 1998. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J Exp Med. 187(11):1893-902.
  • Zamble DB, Jacks T, Lippard SJ. 1998. p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci U S A. 95(11):6163-8.
  • McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, Jacks T. 1998. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 12(8):1121-33.
  • Shaw RJ, McClatchey AI, Jacks T. 1998. Localization and functional domains of the neurofibromatosis type II tumor suppressor, merlin. Cell Growth Differ. 9(4):287-96.
  • Shaw RJ, McClatchey AI, Jacks T. 1998. Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. J Biol Chem. 273(13):7757-64.
  • Brugarolas J, Bronson RT, Jacks T. 1998. p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. J Cell Biol.Apr 20;141(2):503-14.
  • Yamasaki L, Bronson R, Williams BO, Dyson NJ, Harlow E, Jacks T. 1998. Loss of E2F-1 reduces tumorigenesis and extends the lifespan of Rb1(+/-)mice. Nat Genet. 18(4):360-4.
  • Nacht M, Jacks T. 1998. V(D)J recombination is not required for the development of lymphoma in p53-deficient mice. Cell Growth Differ.9(2):131-8.
  • Shaw RJ, Henry M, Solomon F, Jacks T. 1998. RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts. Mol Biol Cell.Feb;9(2):403-19.
  • Lanni JS, Jacks T. 1998. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol. 18(2):1055-64.
  • Mulligan GJ, Wong J, Jacks T. 1998. p130 is dispensable in peripheral T lymphocytes: evidence for functional compensation by p107 and pRB. Mol Cell Biol. 18(1):206-20.
  • Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, Schmitt E, Bronson RT, Umanoff H, Edelmann W, Kucherlapati R, Jacks T. 1997. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11(19):2468-81.
  • Lanni JS, Lowe SW, Licitra EJ, Liu JO, Jacks T. 1997. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc Natl Acad Sci U S A. 94(18):9679-83.
  • Jones JM, Attardi L, Godley LA, Laucirica R, Medina D, Jacks T, Varmus HE, Donehower LA. 1997. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. Cell Growth Differ. 8(8):829-38.
  • Montes de Oca Luna R, Amelse LL, Chavez-Reyes A, Evans SC, Brugarolas J, Jacks T, Lozano G. 1997. Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nat Genet. 16(4):336-7.
  • McClatchey AI, Saotome I, Ramesh V, Gusella JF, Jacks T. 1997. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev. 11(10):1253-65.
  • van der Geer P, Henkemeyer M, Jacks T, Pawson T. 1997. Aberrant Ras regulation and reduced p190 tyrosine phosphorylation in cells lacking p120-Gap. Mol Cell Biol. 17(4):1840-7.
  • Silva AJ, Frankland PW, Marowitz Z, Friedman E, Lazlo G, Cioffi D, Jacks T, Bourtchuladze R. 1997. A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat Genet. 15(3):281-4.
  • Macleod KF, Hu Y, Jacks T. 1996. Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO J. 15(22):6178-88.
  • Novitch BG, Mulligan GJ, Jacks T, Lassar AB. 1996. Skeletal muscle cells lacking the retinoblastoma protein display defects in muscle gene expression and accumulate in S and G2 phases of the cell cycle. J Cell Biol. 135(2):441-56.
  • Nacht M, Strasser A, Chan YR, Harris AW, Schlissel M, Bronson RT, Jacks T. 1996. Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev. 10(16):2055-66.
  • Attardi LD, Lowe SW, Brugarolas J, Jacks T. 1996. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J. 15(14):3693-701.
  • Cobrinik D, Lee MH, Hannon G, Mulligan G, Bronson RT, Dyson N, Harlow E, Beach D, Weinberg RA, Jacks T. 1996. Shared role of the pRB-related p130 and p107 proteins in limb development. Genes Dev. 10(13):1633-44.
  • Lee MH, Williams BO, Mulligan G, Mukai S, Bronson RT, Dyson N, Harlow E, Jacks T. 1996. Targeted disruption of p107: functional overlap between p107 and Rb. Genes Dev. 10(13):1621-32.
  • Yamasaki L, Jacks T, Bronson R, Goillot E, Harlow E, Dyson NJ. 1996. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell. 85(4):537-48.
  • Herrera RE, Sah VP, Williams BO, Makela TP, Weinberg RA, Jacks T. 1996. Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol Cell Biol. 16(5):2402-7.
  • Lehar SM, Nacht M, Jacks T, Vater CA, Chittenden T, Guild BC. 1996. Identification and cloning of EI24, a gene induced by p53 in etoposide-treated cells. Oncogene. 12(6):1181-7.
  • Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K. 1996. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 12(2):144-8.
  • Tischler AS, Shih TS, Williams BO, Jacks T. 1995. Characterization of Pheochromocytomas in a Mouse Strain with a Targeted Disruptive Mutation of the Neurofibromatosis Gene Nf1. Endocr Pathol.Winter;6(4):323-335.
  • Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379(6560):88-91.
  • Henkemeyer M, Rossi DJ, Holmyard DP, Puri MC, Mbamalu G, Harpal K, Shih TS, Jacks T, Pawson T. 1995. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature. 377(6551):695-701.
  • Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 377(6549):552-7.
  • Mombaerts P, Terhorst C, Jacks T, Tonegawa S, Sancho J. 1995. Characterization of immature thymocyte lines derived from T-cell receptor or recombination activating gene 1 and p53 double mutant mice. Proc Natl Acad Sci U S A. 92(16):7420-4.
  • Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. 1995. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet. 10(2):175-80.
  • Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T. 1995. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev.9(8):935-44.
  • Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, Remington L, Jacks T, Brash DE. 1994. Sunburn and p53 in the onset of skin cancer. Nature. 372(6508):773-6.
  • Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. 1994. p53 status and the efficacy of cancer therapy in vivo. Science. 266(5186):807-10.
  • Strasser A, Harris AW, Jacks T, Cory S. 1994. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell. 79(2):329-39.
  • Williams BO, Schmitt EM, Remington L, Bronson RT, Albert DM, Weinberg RA, Jacks T. 1994. Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J. 13(18):4251-9.
  • Morgenbesser SD, Williams BO, Jacks T, DePinho RA. 1994. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature. 371(6492):72-4.
  • Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T. 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 78(4):703-11.
  • Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. 1994. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet. 7(4):480-4.
  • Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. 1994. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet7(3):353-61.
  • Slebos RJ, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T, Hedrick L, Kastan MB, Cho KR. 1994. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci U S A. 91(12):5320-4.
  • Lowe SW, Jacks T, Housman DE, Ruley HE. 1994. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci U S A. 91(6):2026-30.
  • Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. 1994. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 4(1):1-7.
  • Williams BO, Morgenbesser SD, DePinho RA, Jacks T. 1994. Tumorigenic and developmental effects of combined germ-line mutations in Rb and p53. Cold Spring Harb Symp Quant Biol.59:449-57.
  • Lowe SW, Bodis S, Bardeesy N, McClatchey A, Remington L, Ruley HE, Fisher DE, Jacks T, Pelletier J, Housman DE. 1994. Apoptosis and the prognostic significance of p53 mutation. Cold Spring Harb Symp Quant Biol. 59:419-26.
  • Cory S, Strasser A, Jacks T, Corcoran LM, Metz T, Harris AW, Adams JM. 1994. Enhanced cell survival and tumorigenesis. Cold Spring Harb Symp Quant Biol. 59:365-75.
  • Symonds H, Krall L, Remington L, Saenz Robles M, Jacks T, Van Dyke T. 1994. p53-dependent apoptosis in vivo: impact of p53 inactivation on tumorigenesis. Cold Spring Harb Symp Quant Biol. 59:247-57.
  • Hatakeyama M, Herrera RA, Makela T, Dowdy SF, Jacks T, Weinberg RA. 1994. The cancer cell and the cell cycle clock. Cold Spring Harb Symp Quant Biol. 59:1-10.
  • Cobrinik D, Whyte P, Peeper DS, Jacks T, Weinberg RA. 1993. Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev. 7(12A):2392-404.
  • Berges RR, Furuya Y, Remington L, English HF, Jacks T, Isaacs JT. 1993. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci U S A.90(19):8910-4.
  • Lowe SW, Ruley HE, Jacks T, Housman DE. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74(6):957-67.
  • Gregory PE, Gutmann DH, Mitchell A, Park S, Boguski M, Jacks T, Wood DL, Jove R, Collins FS. 1993. Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. Somat Cell Mol Genet. 19(3):265-74.
  • Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362(6423):847-9.
  • Chen J, Gorman JR, Stewart V, Williams B, Jacks T, Alt FW. 1993. Generation of normal lymphocyte populations for Rb-deficient ES cells. Curr. Biol. 3(7):405-13.
  • Corcoran LM, Karvelas M, Nossal GJ, Ye ZS, Jacks T, Baltimore D. 1993. Oct-2, although not required for early B-cell development, is critical for later B-cell maturation and for postnatal survival. Genes Dev. 7(4):570-82.
  • Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71(4):587-97.
  • Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. 1992. Effects of an Rb mutation in the mouse. Nature. 359(6393):295-300.
  • Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 70(6):923-35.
  • Jacks T, Madhani HD, Masiarz FR, Varmus HE. 1988. Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region. Cell. 55(3):447-58.
  • Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ, Varmus HE. 1988. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature. 331(6153):280-3.
  • Jacks T, Townsley K, Varmus HE, Majors J. 1987. Two efficient ribosomal frameshifting events are required for synthesis of mouse mammary tumor virus gag-related polyproteins. Proc Natl Acad Sci U S A. 84(12):4298-302.
  • Jacks T, Varmus HE. 1985. Expression of the Rous sarcoma virus pol gene by ribosomal frameshifting. Science. 230(4731):1237-42.